The gene encoding glycoprotein B (gB) of murine cytomegalovirus (MCMV) strain Smith was identified, sequenced, and expressed by recombinant vaccinia virus. The gB gene was found adjacent to the polymerase gene, as it is in the genome of human cytomegalovirus (HCMV). The open reading frame consists of 2,784 nucleotides capable of encoding a protein of 928 amino acids. Comparison with gB homologs of other herpesviruses revealed a high degree of homology. The similarity between the MCMV gB and the HCMV gB is most prominent, since 45% of the amino acids are identical. In addition, all cysteine residues are at homologous positions, indicating a similar tertiary structure of the two proteins. In contrast to HCMV, the MCNV gB mRNA is a true late transcript. A recombinant vaccinia virus expressing the MCMV gB gene has been constructed (Vac-gB (HSV). A significant fraction of the neutralizing antibodies in human antisera are directed against the proteins of the gC-I complex (4). In addition, antisera raised against vaccinia virus recombinants expressing gB or monoclonal anti-gB antibodies effectively neutralize the virus in vitro (9). These data * Corresponding author.
The gene encoding glycoprotein B (gB) of murine cytomegalovirus (MCMV) strain Smith was identified, sequenced, and expressed by recombinant vaccinia virus. The gB gene was found adjacent to the polymerase gene, as it is in the genome of human cytomegalovirus (HCMV) . The open reading frame consists of 2,784 nucleotides capable of encoding a protein of 928 amino acids. Comparison with gB homologs of other herpesviruses revealed a high degree of homology. The similarity between the MCMV gB and the HCMV gB is most prominent, since 45% of the amino acids are identical. In addition, all cysteine residues are at homologous positions, indicating a similar tertiary structure of the two proteins. In contrast to HCMV, the MCNV gB mRNA Murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV) are members of the subfamily Betaherpesvirinae. HCMV is a ubiquitous human pathogen, but most primary infections do not lead to an apparent disease. However, HCMV is a major cause of serious illness in congenitally infected infants and in immunocompromised individuals (15, 34) . Patients with AIDS, organ allograft recipients, and cancer patients receiving immunosuppressive drugs develop severe and often fatal HCMV infections. At present only live, attenuated virus strains which still bear the risk of latent infections are available as vaccines. The severity of the CMV infection may be moderated by the administration of anti-CMV antibodies (37) . The efficacy of the vaccines and the value of the antibody treatment are controversial (41) . A better characterization and understanding of the host immune response against CMV would facilitate the search for new and improved vaccines and targeted treatments.
Envelope glycoproteins of herpesviruses represent dominant antigens for both the cellular and the humoral immune response (40) . Their property of serving as targets for neutralizing antibodies is of particular interest. The major envelope glycoprotein complex of HCMV is called gC-I (16) . The glycoprotein complex gC-I consists of two mature glycoproteins with molecular masses of 93 to 130 kDa and 52 to 58 kDa, derived by proteolytic cleavage from a precursor glycoprotein of 150 to 170 kDa (4, 9, 38) . The proteins are encoded by a gene referred to as gB by Cranage et al. (9) and Mach et al. (30) because of its sequence homology with the glycoprotein B (gB) gene of herpes simplex virus (HSV). A significant fraction of the neutralizing antibodies in human antisera are directed against the proteins of the gC-I complex (4) . In addition, antisera raised against vaccinia virus recombinants expressing gB or monoclonal anti-gB antibodies effectively neutralize the virus in vitro (9) . These data * Corresponding author.
suggest that the glycoprotein B is an important target for the humoral immune response against HCMV.
Due to the species specificity of HCMV, in vivo experiments cannot be conducted. Therefore, the availability of an appropriate animal model is important. MCMV has been useful for studying CMV infections because of the many similarities between MCMV and HCMV in biology and pathogenesis. Thus, the study of the murine immune response to MCMV may be valuable for understanding the situation in humans.
In this report, we describe the identification and sequencing of a gene whose primary translation product shows characteristics of a glycoprotein. Comparison of the deduced amino acid sequence of the protein with sequences of other herpesvirus glycoproteins reveals extensive homology to the glycoprotein B of HCMV. The gB gene was expressed by recombinant vaccinia virus. The Vac-gB recombinant induced neutralizing antibodies in mice and thus provides a tool to test the usefulness of a gB subunit vaccine in an animal model.
MATERIALS AND METHODS
Virus and cell culture. MCMV (mouse salivary gland virus strain Smith [ATCC VR-194]) was propagated on BALB/c mouse embryonal fibroblasts as described previously (18) . CV-1 cells, used for the propagation of vaccinia viruses, were maintained in Dulbecco's modified Eagle medium supplemented with 10% (vol/vol) fetal calf serum, 2 mM L-glutamine, 100 ,ug of streptomycin per ml, and 100 U of penicillin per ml. Mouse embryonal fibroblasts were MCMV infected with 20 PFU per cell by using the technique of centrifugal enhancement of infectivity at 800 x g for 30 min. by a modified version of the dideoxy sequencing method (42) using Bal 31-and exonuclease III-generated subclones of the 3.5-kb PvuII fragment (Fig. 1, p3 .5). The 3'-terminal part of the nucleic acid sequence (nt 1400 to 2300) was obtained by the method of Maxam and Gilbert (32) with modifications reported previously (19) . Both strands were sequenced, and overlapping clones were used to confirm the sequence. The Genetics Computer Group software package version 7.0 from April 1991 (10) was used for the analysis of the nucleic acid sequence, for the deduction of the amino acid sequence, and for the prediction of the secondary structure of the gB protein. The herpesvirus gB amino acid sequences from the GenBank data base (release 69 from September 1991) were compared.
Northern blot (RNA) analysis and nuclease protection. At different time points postinfection, whole-cell RNA was prepared from MCMV-infected cells and mock-infected control cells following published procedures (7) . The RNA was size fractionated by gel electrophoresis, transferred to nitrocellulose filters, and hybridized to a gB-specific, 32P-labeled DNA probe. For the S1 analysis, whole-cell RNA was hybridized to 32P end-labeled DNA fragments and digested with nuclease S1 as described previously (19) . Nucleaseresistant fragments were size fractionated on denaturing sequencing gels.
Rapid amplification of cDNA ends. The 3' end of the gB mRNAs was determined according to the protocol of Frohman et al. (14) with the oligonucleotides (dT)17-R1-RO (5'-AAGGATCCGTCGACATCGATAATACGACTCACTA TAGGGATTTTTTTTTTTTTTTTT-3'), RO (5'-AAGGATC CGTCGACATC-3'), and gB.End (5'-CAGAATTCGTATC TCATCTTCACGAGGC-3'). The primer gB.End corresponds to positions 2650 to 2669 in Fig. 2 .
Production of recombinant vaccinia viruses. Vaccinia virus recombinants expressing a truncated (Vac-gB626) and the complete (Vac-gB) gB open reading frame (ORF) were generated. For the construction of the recombination plasmid pCS-gB626, a 3.5-kb PvuII subclone (Fig. 1, p3.5 Attempts to clone the complete gB ORF into a multicopy plasmid were not successful. Therefore, the gB ORF originally cloned in the low-copy-number plasmid pACYC177 was flanked with the vaccinia virus thymidine kinase sequences and the vaccinia virus p7.5 promoter. In detail, the HindIII-D fragment cloned into pACYC177 (12) was digested with EcoRI and religated, thereby removing nearly the complete HindIII-D fragment sequences upstream of the gB gene and also part of the gB ORF. Sequences downstream of the gB gene and 600 bp of the vector pACYC177 were removed by digestion with DraIII, and religation resulted in the plasmid pDra (Fig. 1) . The gB ORF was restored by insertion of a 1.3-kb HindIII-XbaI fragment from a PstI-XbaI subclone of the HindIII-D fragment (Fig. 1 Consequently, the vaccinia virus recombinant Vac-gB contains the gB ORF and 3.5 kb of pACYC177 vector sequences downstream of the p7.5 promoter. The vaccinia virus recombinants were produced by following established procedures (31) using the DNA of vaccinia virus strain Copenhagen and the temperature-sensitive mutant ts7 (11) .
Preparation of antisera and immunoprecipitation. Antiserum from latently MCMV-infected BALB/c mice was used for the detection of the gB protein in Vac-gB-infected cells. A gB-specific antiserum was prepared by infection of rabbits with the vaccinia virus recombinant Vac-gB626. Another gB-specific antiserum used for neutralization assay was prepared by infection of mice with the Vac-gB recombinant. The monospecific rabbit serum was used to identify the glycoprotein B in MCMV-infected cells. Immunoprecipitations were performed as described previously (20) . In brief, samples of cell lysates were incubated with S ,u of antiserum or ascitic fluid. A 50% protein A-Sepharose suspension (Pharmacia) was preincubated with rabbit antibodies specific for mouse immunoglobulin G (Dianova) before addition to the antigen-antibody complexes. The precipitated proteins were separated by sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis.
MCMV neutralization assay. The neutralizing activity of gB-specific mouse antisera was determined by a plaque reduction assay on mouse embryonal fibroblast monolayers grown in 48-well flat-bottom plates. Serum (23) . Assuming colinearity between the MCMV genome and the genomes of other herpesviruses, especially HCMV, the putative MCMV gB homolog was expected to be located within the MCMV HindIII-D fragment upstream of the polymerase gene ( Fig. 1) (Fig. 3, lane 6 ). On the basis of the size of the gB mRNA predicted from the nucleotide sequence, the 3.3-kb transcript is expected to represent the gB mRNA. In addition, two bands of higher molecular masses, which show the same expression kinetics as the 3.3-kb mRNA, were visible. The gB-specific transcript of 3.3 kb appeared at 16 h p.i. (Fig. 3, (Fig. 3, lane 7) . Thus, the transcription of the gB gene is restricted to the late phase of infection.
Identification of the 5' and 3' ends of the gB transcript(s). Nuclease SI analysis was performed to determine the 5' and 3' ends of the gB transcript(s). To map the position of the 5' end of the gB mRNA, a 465-nt fragment was used (Fig. 4A (Fig. 4A, lanes 3 and 4) (33a) .
For the location of the 3' end of the gB mRNAs, a SalI-Stul fragment (map units 0.366 to 0.361; Fig. 1 ) was used for SI nuclease analysis (Fig. 4B, lane 1) . The (33) . The protected fragment of 870 nt locates the 3' end of the gB mRNAs between the first polyadenylation signal and the first YGTGTTYY signal. The two smaller protected fragments (Fig. 4B, lanes 3 and 4) probably result from overdigestion of the DNA-RNA hybrids due to insufficient hybridization as a consequence of AT-rich sequences around the polyadenylation signal. To determine the 3' ends of the gB mRNAs more precisely, cDNA was synthesized from the gB mRNAs. The 3' ends of the cDNAs were amplified according to the protocol of Frohman et al. (14) by using the primers Rl and gB.End. The amplified fragment of approximately 550 nt was cloned into pUC19 and subjected to sequence analysis. According to the sequence data, the 3' end of the gB mRNAs is located at the C residue at position 3147 (Fig. 2) , 15 nt downstream of the first polyadenylation signal. There is no indication that the second polyadenylation signal is also used. Therefore, we conclude that the mRNAs stop predominantly after the first polyadenylation signal.
Primary amino acid sequence and secondary structure analysis of the MCMV glycoprotein B. The amino acid sequence of the MCMV glycoprotein B was deduced from the nucleic acid sequence of the identified ORF (Fig. 5) . Hydrophobic and hydrophilic parts of the protein were determined according to the method of Chou and Fasman (8) . Several ATGs are located in the 5' part of the mRNAs. The first two ATGs are almost immediately followed by stop codons and therefore represent minicistrons known from many eukaryotic and viral mRNAs (26) . It is not known whether they are used. The following two ATGs are both in frame with the long ORF. Since the third ATG of the mRNA is the first ATG of the long ORF and conforms as well to the Kozak consensus sequence CC(A/G)CCATGC (25) as the second one, translation probably starts here. The gB transcript is translated into a 928-aa protein (Fig. 5) (Fig. 5, overlined) . The Chou-Fasman analysis shows an extended hydrophobic region near the C terminus of the gB, indicating a potential transmembrane domain (data not shown). This putative transmembrane region spans aa 740 to 804 (Fig. 5, boxed) . The remaining, basically hydrophilic aa 805 to 928 (Fig. 5) probably form the cytoplasmic tail of the protein.
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Comparison of the MCMV gB with the gB homologs of other herpesviruses. To unequivocally demonstrate that the identified gene is the gB homolog of MCMV, the deduced amino acid sequence of the protein (Fig. 5, upper line) was compared with the amino acid sequence of HCMV gB (Fig.  5, bottom line) . The gB homologs of the HCMV strains AD169 and Towne are composed of 906 (9) and 907 aa (39), respectively. The MCMV gB and the HCMV gB have 45% identical amino acids that are located mainly in the central portion of the protein, while the N and C termini show little or no identity (Fig. 5) . Since all 11 cysteine residues following the signal peptide are conserved (Fig. 5, asterisks) , the proteins probably possess similar tertiary structures. Eight of the 12 potential N glycosylation sites of the MCMV gB are found at the same positions as the glycosylation sites of the HCMV gB (Fig. 5, underlined) . The gB of HCMV is translated as a polyprotein and subsequently cleaved into two subunits (21, 39) . The potential cleavage sites of the HCMV gB proteins are the motifs RTKR/STD463 (Towne) (39) and RTRR/STS463 (AD-169) (21) . A similar motif (RRKR/ SFD500) was detected in MCMV and probably represents the proteolytic cleavage site.
The amino acid sequence of the MCMV gB protein was also compared by dot matrix analysis with those of the gB homologs of HCMV, Epstein-Barr virus (EBV) and HSV type 1 (HSV-1) (Fig. 6 ). The MCMV protein is similar to all other gB homologs, the transmembrane region being more conserved than other parts of the protein. The Proteins were precipitated from cell lysates by a monospecific serum produced in a rabbit against the vaccinia virus recombinant Vac-gB626. The autoradiography of the gel is shown in Fig. 7A . The gB-specific serum precipitated polypeptides with apparent molecular masses of 130, 105, and 52 kDa from lysates of MCMV-infected cells but not from lysates of noninfected cells (Fig. 7A, lanes 3 and 4) . The sizes of the proteins are similar to those reported for the HCMV gB.
Expression (Fig. 7B, lane 4) , which comigrated with the MCMV gB precursor (compare Fig. 7A, lane 4 and Fig. 7B, lane 4) .
Identity of the MCMV glycoprotein B with the MCMV major envelope glycoprotein. The major envelope glycoprotein of MCMV has been described by Loh et al. (27, 28) . Three proteins, gp 150, gp 52, and gplO5, which were derived from a common precursor of 128 kDa were identified on the surface of the virion (27) . This closely resembles the situation described for the HCMV gB gene products. To test whether the proteins of the major envelope glycoprotein complex are the translation products of the identified gB gene, the protein expressed by the recombinant vaccinia virus Vac-gB was tested with the monoclonal antibody 2E8.21A against the major envelope glycoprotein (28) . The monoclonal antibody precipitated proteins of 130, 105, and 52 kDa from lysates of MCMV-infected cells (Fig. 8, lane 2) . Proteins of the same size were precipitated with the gBspecific antiserum (Fig. 7A, lane 4) . In Vac-gB-infected cells, a protein which has the same molecular mass as that of the gB precursor form was detected (Fig. 8, lane 4) . Thus, the glycoprotein B and the major envelope glycoprotein are identical.
Induction of neutralizing antibodies by the Vac-gB recombinant. A gB-specific antiserum was raised in mice by infection with the Vac-gB recombinant and tested for neutralizing activity in a plaque reduction assay. A mouse preimmune serum and an anti-MCMV serum raised in mice by infection with MCMV were included in the plaque reduction assay for comparison. Whereas the mouse preimmune serum was not able to neutralize the virus, the anti-gB and anti-MCMV antisera showed considerable neutralizing activity ( Table 1 showed a higher level of neutralizing activity and was also capable of neutralizing the virus in the absence of complement, although the complement-independent neutralizing activity was weak.
DISCUSSION
The MCMV glycoprotein B gene was identified, sequenced, and expressed by recombinant vaccinia virus. The gene product in Vac-gB-infected cells showed the same migration property as the gB precursor in MCMV-infected cells. Although the mature gB subunits were not found in Vac-gB-infected cells, mice immunized with the recombinant developed antibodies that neutralized MCMV in vitro.
The identification of the MCMV gB gene was possible because the gene is located in a conserved block of genes (23) . The genes for glycoprotein B, a putative transport protein, and the major DNA-binding protein are organized in exactly the same order in HCMV, EBV, and HSV-1. The viral DNA polymerase gene is located downstream of the gB gene in HCMV and EBV but not in HSV-1 (23) . Since MCMV is more related to HCMV than to other herpesviruses, the MCMV gB gene was expected to be located upstream of the polymerase gene. Sequencing of this region revealed an ORF of 2,784 nt.
The assumption that the identified ORF represents the gB gene was further strengthened by the high degree of homology between the deduced amino acid sequence of the putative MCMV gB homolog and the amino acid sequences of the gB homologs of HCMV, HSV-1, and EBV. The highest degree of homology was found between the gBs of the two members of the betaherpesviruses, MCMV and HCMV. Considerable homology to gBs of other herpesviruses, e.g., alphaherpesviruses (HSV-1) and gammaherpesviruses (EBV), was also found. The recently published sequence of the carboxy terminus of the MCMV gB of strain K181 is almost identical to our sequence, with the exception of some amino acid exchanges and a small deletion of 7 aa at position 805 (13) . These data indicate that the function of the gB allows only subtle differences at certain positions. The deletion might point to a less important region of the protein.
Comparisons of the amino acid sequences of all known gB homologs show that a significant portion of the amino acid sequence is conserved among all herpesviruses (9, 22) . It has also been reported previously that 10 cysteine residues are perfectly aligned in all herpesvirus gB homologs (22) . Therefore, the tertiary structure of the proteins appears to be conserved too. This notion is confirmed by the fact that the gB homolog from one herpesvirus can functionally comple- (39) . Transcription of the MCMV gB gene is blocked by the DNA replication inhibitor phosphonoacetic acid. Thus, the MCMV gB gene is a true late gene and there is no evidence for posttranscriptional regulation such as that suggested for the HCMV gB gene (strain Towne) (39). However, despite the different transcriptional patterns, the expression of the protein is restricted to the late phase in both viruses. In addition to the expected 3.3-kb gB-specific transcript, two RNAs of higher molecular masses are visible. The existence of additional, longer transcripts has also been reported for the HCMV gB gene (39) and the HCMV and MCMV polymerase genes (13, 24) . It has been proposed that these HCMV transcripts might represent read-through products of the gB transcript which would normally terminate at the polyadenylation signal within the DNA polymerasecoding region (24) . Whether a similar situation exists for the larger MCMV transcripts remains to be established.
To conduct in vivo protection experiments, the gB ORF was engineered into vaccinia virus. At first, it was possible to clone only part of the gB gene into a vaccinia virus recombination plasmid. For unknown reasons, the whole gB ORF could not be inserted into a commonly used vaccinia virus recombination plasmid. Similar problems have been reported elsewhere for the cloning of the HSV gB gene (5) and the HCMV gB gene (29) . These problems could be due to a gene product which is toxic for the bacteria. Therefore, instead of subcloning the gene, it was flanked by the vaccinia virus sequences from recombination vectors pGS62 and pCS43. The resulting recombination vector was based on the low-copy-number plasmid pACYC177. Because of a copy number of only 20 plasmids per bacterial chromosome (6), the bacteria are probably able to tolerate small amounts of the putative toxic gene product.
The protein expressed by the recombinant vaccinia virus Vac-gB has the same size (130 kDa) as the gB precursor protein in MCMV-infected cells. However, the subunits of 105 and 52 kDa, which are visible in MCMV-infected cells, could not be detected in Vac-gB-infected cells. For the HCMV gB, it has been proposed that a cellular protease cleaves the protein (38) , which probably belongs to the subtilisinlike serine protease family (2) . The putative cleavage site of the MCMV gB corresponds to the consensus cleavage motif of these proteases. For vaccinia virus-expressed substrates, it has been shown that cleavage by this serine protease family does not occur late in infection (3). In fact, when Vac-gB-infected cells were labeled from 3.5 to 6.5 h after infection, faint traces of the processed gB subunits could be detected (data not shown).
Immunization with the Vac-gB recombinant induced a considerable level of neutralizing activity. However, the neutralizing activity level of the anti-MCMV serum was higher. It has been reported elsewhere that a significant portion of the human humoral immune response against HCMV is directed against the HCMV gB (4). Further experiments will clarify whether the higher neutralizing activity of the anti-MCMV serum is due to a titer of anti-gB antibodies higher than that of the Vac-gB serum or whether the anti-MCMV serum also contains neutralizing antibodies against other MCMV proteins.
In MCMV-infected cells, three proteins with the apparent molecular masses of 130, 105, and 52 kDa were detected with an anti-gB serum. Thus, the products of the MCMV gB gene have approximately the same sizes as their HCMV counterparts (4, 9, 39) . In addition, the proteins have exactly the same sizes as the proteins of the major envelope glycoprotein complex of MCMV (27, 28) . The reactivity of the monoclonal antibodies 2E8.21A and 8G5.21A (28) with the Vac-gB gene product in Western blotting (data not shown) and immunoprecipitations confirmed the identity between the gB gene products and the major envelope glycoprotein complex.
As outlined above, the herpesvirus gB homologs are extremely conserved in several aspects. Thus, the MCMV gB is suitable for studying the immune response against glycoprotein B in a natural virus-host model. The Vac-gB construct will enable us to study the protective potential of this protein. This may be of interest in view of the use of the glycoprotein B as a subunit vaccine.
